Literature DB >> 16492917

Effect of acid suppression on molecular predictors for esophageal cancer.

Pierre Lao-Sirieix1, Amanda Roy, Claire Worrall, Sarah L Vowler, Sue Gardiner, Rebecca C Fitzgerald.   

Abstract

BACKGROUND: Gastroesophageal reflux disease is a risk factor for the development of Barrett's esophagus and esophageal adenocarcinoma. The effect of antireflux therapy on the incidence of esophageal adenocarcinoma is unknown. Acid exposure in vitro induces hyperproliferation via a cyclooxygenase-2 (COX-2) dependent mechanism. Epidemiologic and animal studies suggest that COX inhibitors decrease the incidence of esophageal adenocarcinoma. AIM: To study the differential effect of complete compared with incomplete acid suppression on proliferation, apoptosis, and COX-2. PATIENTS AND METHODS: Fifty-one patients with Barrett's esophagus who underwent pH monitoring were divided into two groups according to their DeMeester score: 32 acid-suppressed patients (group 1) and 19 patients with abnormally high acid exposure (group 2). Slides from biopsies taken 3 months before and 4 and 12 months after pH monitoring were stained for Mcm2, COX-2, c-myc, and cleaved caspase-3 (marker of apoptosis).
RESULTS: There was no evidence of a difference between the two groups in terms of age, gender ratio, medication, dysplasia status, and the expression levels of any marker before pH monitoring. In group 1, Mcm2 expression decreased in the luminal surface and throughout the tissue 12 months after monitoring when compared with the two previous time points (P < 0.05). The levels of COX-2 increased overtime (P < 0.01 in group 1, not significant in group 2). There was no correlation between Mcm2 and COX-2 expression. Acid suppression had no effect on c-myc or apoptosis.
CONCLUSION: Long-term acid suppression reduces proliferation in Barrett's esophagus samples but has no advantageous effect on c-myc, apoptosis, or COX-2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16492917     DOI: 10.1158/1055-9965.EPI-05-0528

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  15 in total

1.  Chemoprevention of esophageal adenocarcinoma.

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

2.  Barrett's esophagus: endoscopic treatments II.

Authors:  Bruce D Greenwald; Charles J Lightdale; Julian A Abrams; John D Horwhat; Ram Chuttani; Srinadh Komanduri; Melissa P Upton; Henry D Appelman; Helen M Shields; Nicholas J Shaheen; Stephen J Sontag
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

3.  Deletion at fragile sites is a common and early event in Barrett's esophagus.

Authors:  Lisa A Lai; Rumen Kostadinov; Michael T Barrett; Daniel A Peiffer; Dimitry Pokholok; Robert Odze; Carissa A Sanchez; Carlo C Maley; Brian J Reid; Kevin L Gunderson; Peter S Rabinovitch
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

4.  Effect of alpha-tocopherol, N-acetylcysteine and omeprazole on esophageal adenocarcinoma formation in a rat surgical model.

Authors:  Jing Hao; Bin Zhang; Ba Liu; Maojung Lee; Xingpei Hao; Kenneth R Reuhl; Xiaoxin Chen; Chung S Yang
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

5.  Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis.

Authors:  Zehra B Omer; Ashwin N Ananthakrishnan; Kevin J Nattinger; Elisabeth B Cole; Jesse J Lin; Chung Yin Kong; Chin Hur
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-15       Impact factor: 11.382

6.  Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients.

Authors:  Bhaskar Banerjee; Nicholas J Shaheen; Jessica A Martinez; Chiu-Hsieh Hsu; Eugene Trowers; Blake A Gibson; Gary Della'Zanna; Ellen Richmond; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2016-02-23

7.  Chemoprevention in Barrett's esophagus: are we there yet, are we there yet...?

Authors:  Douglas A Corley
Journal:  Clin Gastroenterol Hepatol       Date:  2009-09-16       Impact factor: 11.382

8.  Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus.

Authors:  Judy S Wang; Andrea Varro; Charles J Lightdale; Nantaporn Lertkowit; Kristen N Slack; Michael L Fingerhood; Wei Yann Tsai; Timothy C Wang; Julian A Abrams
Journal:  Am J Gastroenterol       Date:  2009-11-10       Impact factor: 10.864

9.  Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.

Authors:  Dennis L Chao; Carissa A Sanchez; Patricia C Galipeau; Patricia L Blount; Thomas G Paulson; David S Cowan; Kamran Ayub; Robert D Odze; Peter S Rabinovitch; Brian J Reid
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

10.  Quantitation of spatial and temporal variability of biomarkers for Barrett's Esophagus.

Authors:  J Nwachokor; O Tawfik; M Danley; S Mathur; J House; P Sharma; L K Christenson; A Bansal
Journal:  Dis Esophagus       Date:  2017-09-01       Impact factor: 3.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.